University of Wisconsin, Madison
Welcome,         Profile    Billing    Logout  
 83 Trials 
161 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
LoConte, Noelle
GIANT, NCT04233866: Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

Active, not recruiting
2
176
US
Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Gemcitabine Hydrochloride, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Leucovorin, Folinic acid, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Liposomal Irinotecan, Irinotecan Liposome, MM-398, nal-IRI, Nanoliposomal Irinotecan, Nanoparticle Liposome Formulation of Irinotecan, Onivyde, PEP02, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, protein-bound paclitaxel, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
12/25
12/25
Actuate 1801, NCT03678883 / 2018-003739-32: 9-ING-41 in Patients with Advanced Cancers

Active, not recruiting
2
350
Europe, Canada, US
9-ING-41, Gemcitabine - 21 day cycle, Gemzar, Doxorubicin., Doxil, Adriamycin, Lomustine, CCNU, Gleostine, Carboplatin., Paraplatin, Nab paclitaxel., Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel, Paclitaxel., Taxol, Gemcitabine - 28 day cycle, Irinotecan, Camptosar
Actuate Therapeutics Inc., Actuate Therapeutics Inc
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
01/25
01/26
Teng, Joyce
VAPAUS, NCT05180708: A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita

Completed
3
87
Europe, US
QTORIN 3.9% rapamycin anhydrous gel, Vehicle
Palvella Therapeutics, Inc.
Pachyonychia Congenita
06/23
06/23
SELVA, NCT06239480: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations

Recruiting
3
40
US
QTORIN 3.9% Rapamycin Anhydrous Gel
Palvella Therapeutics, Inc., FDA Office of Orphan Products Development
Microcystic Lymphatic Malformation
01/26
07/26
NCT06073132: An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

Recruiting
2/3
80
Europe, US, RoW
AC-203, Vehicle
TWi Biotechnology, Inc.
Generalized Epidermolysis Bullosa Simplex
08/25
03/26
EPIK-L1, NCT05948943: Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

Recruiting
2/3
230
Europe, US, RoW
Alpelisib, BYL719, Placebo
Novartis Pharmaceuticals
Lymphatic Malformations
10/27
05/30
PALV-04, NCT04893486: CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome

Completed
2
73
Europe, US
PTX-022, Vehicle comparator
Palvella Therapeutics, Inc.
BCCs in Gorlin Syndrome Patients
03/23
03/23
NCT04258046: Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation

Recruiting
2
30
US
Trametinib tablet
Stanford University, Boston Children's Hospital
Venous Malformation, Arterial Disease
12/24
12/24
TAMES, NCT05062070: Safety and Efficacy of Topical TolaSure Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex

Completed
1/2
6
US
TolaSure Topical Gel, Active Ingredient BM-3103, Vehicle Topical Gel, TolaSure Vehicle Gel
BioMendics, LLC
Epidermolysis Bullosa Simplex
06/23
06/23
NCT02057614: Topical Sirolimus for Plantar Keratoderma in Adults With Pachyonychia Congenita (PC)

Recruiting
1
15
US
Topical Sirolimus
Stanford University, TransDerm, Inc., Pachyonychia Congenita Project
Pachyonychia Congenita, Plantar Keratoderma
12/14
 
TSTIH, NCT06273111: Topical Simvastatin for Treating Infantile Hemangioma

Not yet recruiting
1
12
US
5% simvastatin ointment
Joyce Teng, Stanford University
Hemangioma Skin
07/25
12/25
NCT03269474: Computational Drug Repurposing for All EBS Cases

Recruiting
N/A
60
US
Experimental Group
Joyce Teng
Epidermolysis Bullosa, Healthy, Genetic Skin Disease, Epidermolysis Bullosa Simplex, Epidermolysis Bullosa, Junctional, Epidermolysis Bullosa Dystrophica
12/24
12/24
Campbell, Toby
ASTRIDE, NCT05468489: To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Recruiting
3
200
US
Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide)
Shanghai Henlius Biotech
Extensive Stage Small Cell Lung Cancer
04/25
12/25
NCT04379570: Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

Recruiting
3
1180
US
Educational Intervention, Text Message-based Navigation Intervention, Motivational Interviewing, Best Practice, Standard of Care, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Anatomic Stage I Breast Cancer AJCC V8, Anatomic Stage II Breast Cancer AJCC V8, Anatomic Stage III Breast Cancer AJCC V8, HER2 Negative Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC V8, Prognostic Stage II Breast Cancer AJCC V8, Prognostic Stage III Breast Cancer AJCC V8
10/26
10/26
REACH PC, NCT03375489: Early Integrated Telehealth Versus In-Person Palliative Care for Patients With Lung Cancer

Active, not recruiting
N/A
1250
US
Telehealth, In-person PC
Massachusetts General Hospital, Patient-Centered Outcomes Research Institute, Palliative Care Research Cooperative Group
Lung Cancer
12/23
12/24
Benca, Ruth M
NCT05771844: Home Sleep Therapy for Older Adults With MCI

Recruiting
N/A
82
US
Transcranial Electrical Stimulation, SleepWISP (Wireless Interface Sensor Pod)
Brain Electrophysiology Laboratory Company, National Institute on Aging (NIA), Wake Forest University
Mild Cognitive Impairment, Sleep, Transcranial Electrical Stimulation, Machine Learning, Memory
06/26
06/26
Lee, Kenneth
NCT01843504: Platelet-Rich Plasma (PRP) Injection for the Treatment of Chronic Patellar Tendinopathy

Completed
2
29
US
platelet rich plasma, saline
University of Wisconsin, Madison
Chronic Patellar Tendinopathy, Chronic PT
02/24
02/24
NCT04794335: Visceral Afferents

Withdrawn
N/A
224
US
University of Pittsburgh, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Inflammatory Bowel Diseases
04/25
04/25
Sleep SMART, NCT03812653: Sleep for Stroke Management and Recovery Trial

Recruiting
N/A
3062
US
CPAP
University of Michigan, National Institute of Neurological Disorders and Stroke (NINDS), FusionHealth LLC, Medical University of South Carolina, University of Cincinnati
Ischemic Stroke, Sleep Apnea, Sleep Apnea, Obstructive, Stroke, CPAP, Telemedicine, Home Sleep Apnea Test, Randomized Clinical Trial, Multicenter Trial
11/26
11/26
Cho, Steve
CLARIFY, NCT06056830: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Recruiting
3
383
US, RoW
64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Prostate Cancer, Prostatic Neoplasms
02/25
02/25
NCI-2018-00466, NCT03302156: PSMA PET and MRI in Gynecological Cancers

Terminated
2
15
US
PSMA-based 18F-DCFPyL PET tracer, PSMA
University of Wisconsin, Madison
Gynecologic Cancer
01/20
01/20
NCT04573231: Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

Recruiting
2
13
US
18F-DCFPyL
University of Wisconsin, Madison
Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
11/25
11/25
NCT05293626: Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND4 Mutations

Active, not recruiting
1/2
12
US
NR082 Injection, Injection needle, Syringe
Neurophth Therapeutics Inc
Leber Hereditary Optic Neuropathy (LHON)
07/25
12/29
NCT03232164: PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer

Completed
1
126
US
18F-DCFPyL PET
University of Wisconsin, Madison
Prostate Cancer, Prostate Neoplasm
11/24
11/24
NCT06122610: Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

Recruiting
1
10
US
Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT), Photon Emission Tomography / CT (PET/CT), 64Cu-Dotatate, Detectnet, 177Lu-Dotatate, Lutathera®
University of Wisconsin, Madison
Neuroendocrine Tumors, Somatostatin Receptor-positive Neuroendocrine Tumor
04/25
04/25
NCT06199713: Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients

Recruiting
N/A
24
US
18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography, 18F-FDG PET/CT
University of Wisconsin, Madison
Melanoma, Melanoma Stage III, Melanoma Stage IV, Unresectable Melanoma
01/26
01/29
VENICE, NCT05280366: STREAMLINE®SURGICAL SYSTEM Compared to iStent Inject W® in Patients With Open-Angle Glaucoma

Active, not recruiting
N/A
150
US, RoW
Streamline Surgical System, iStent Inject W
New World Medical, Inc.
Open Angle Glaucoma
06/26
06/26
Reeder, Scott B
NCT02025543: Confounder-Corrected Quantitative MRI Biomarker of Hepatic Iron Content

Enrolling by invitation
N/A
220
US
MRI, Magnetic Resonance Imaging
University of Wisconsin, Madison, Johns Hopkins University, Stanford University, University of Texas, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Iron Overload, Hemochromatosis, Hemosiderosis
09/25
09/25
NCT03674528: Technical Validation of MR Biomarkers of Obesity-Associated NAFLD

Completed
N/A
152
US
Magnetic Resonance Elastography (MRE), MRI, Liver biopsy, Intraoperative Biopsy
University of Wisconsin, Madison, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), GE Healthcare, Pfizer, Siemens Medical Solutions, National Center for Advancing Translational Sciences (NCATS)
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
06/24
06/24
NCT04867954: Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis

Recruiting
N/A
141
US
Ensure Plus®, Pre-clinical validation contrast enhanced MRI, MRI, Clinical validation MRI, Pre-clinical validation contrast enhanced MRI + fasting
University of Wisconsin, Madison, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Cirrhosis, Liver, Gastroesophageal Varices
04/25
04/25
NCT05294471: Fully Automated High-Throughput Quantitative MRI of the Liver

Recruiting
N/A
190
US
Non-contrast MRI with novel MRI software
University of Wisconsin, Madison, National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Healthy, Iron Overload, Liver Fat
09/26
09/26
Lerner, Susan M
PREVENT-HCV, NCT05653232: Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients

Recruiting
N/A
120
US
Prophylaxis (P2W), Transmit and Treat (T&T)
Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID)
HCV
09/25
03/27
Prabhakaran, Vivek
NCT02098265: A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device

Recruiting
N/A
288
US
Functional Electric Stimulation (FES), Behavioral Assessments, Magnetic Resonance Imaging, EEG, Electroencephalography, RecoveriX, Delay, BCI-FES
University of Wisconsin, Madison, American Heart Association
Stroke
06/25
06/25
NCT04141774: Stroke Rehabilitation Using Brain-Computer Interface (BCI) Technology

Completed
N/A
84
US
Functional Electric Stimulation (FES), Behavioral Assessments, Magnetic Resonance Imaging, EEG, Electroencephalography
University of Wisconsin, Madison, National Institute of Neurological Disorders and Stroke (NINDS)
Stroke
12/24
12/24
Yang, Paul
NCT04850118: A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP

Recruiting
2/3
75
Europe, US, RoW
rAAV2tYF-GRK1-hRPGRco, AGTC-501, Control, Untreated Control Group
Beacon Therapeutics
X-Linked Retinitis Pigmentosa
08/25
10/29
POLARIS, NCT06435000: An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

Recruiting
N/A
75
Europe, US
Splice Bio
Stargardt, Stargardt's Disease, Stargardt Disease, STGD1
12/26
02/27
Barroilhet, Lisa
NRG-GY019, NCT04095364: Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recruiting
3
450
Europe, Canada, US, RoW
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Imaging Technique, Diagnostic Imaging Technique, Image Type, Imaging, Imaging (procedure), imaging procedure, Imaging Procedures, imaging type, IMAGING_METHOD, imaging_type, Medical Imaging, Type of imaging, Letrozole, CGS 20267, Femara, Fempro, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
NRG Oncology, National Cancer Institute (NCI)
Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
02/27
02/28
NCT04575935: Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

Recruiting
3
580
US
Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Laparotomy, Minimally Invasive Surgery, Minimally-Invasive Surgery, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Ovarian Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor, Fallopian Tube Serous Neoplasm, Fallopian Tube Transitional Cell Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8
12/28
12/28
NCI-2018-00466, NCT03302156: PSMA PET and MRI in Gynecological Cancers

Terminated
2
15
US
PSMA-based 18F-DCFPyL PET tracer, PSMA
University of Wisconsin, Madison
Gynecologic Cancer
01/20
01/20
NCT06184750: Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

Recruiting
2
200
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Mammography, MG, Questionnaire Administration, Tamoxifen, TMX
National Cancer Institute (NCI)
Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Estrogen Receptor-Positive Breast Carcinoma
07/27
07/27
DENALI, NCT05128825: A Study of ZN-c3 in Subjects With High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Active, not recruiting
2
102
Europe, US, RoW
ZN-c3, azenosertib
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
04/25
10/25
NCT06557733: An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis

Not yet recruiting
2
38
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, EP2/EP4 Antagonist TPST-1495, Dual EP2/4 Antagonist TPST-1495, PGE2 EP2/EP4 Receptor Antagonist TPST-1495, Prostaglandin E2 Receptor EP2/EP4 Antagonist TPST-1495, TPST 1495, TPST-1495, TPST1495, Esophagogastroduodenoscopy, EGD, Upper Endoscopy, Gastrointestinal Endoscopy, Enteroscopy, Questionnaire Administration
National Cancer Institute (NCI)
Familial Adenomatous Polyposis
12/26
12/26
NCT04092270: A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Active, not recruiting
1
54
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Pegylated Liposomal Doxorubicin Hydrochloride, ATI-0918, Caelyx, Dox-SL, Doxil, Doxilen, Doxorubicin HCl Liposomal, Doxorubicin HCl Liposome, Doxorubicin Hydrochloride Liposome, Duomeisu, Evacet, LipoDox, Lipodox 50, Liposomal Adriamycin, Liposomal Doxorubicin Hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, Pegylated Liposomal Doxorubicin, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99, Peposertib, 3-Pyridazinemethanol, alpha-(2-Chloro-4-fluoro-5-(7-(4-morpholinyl)-4-quinazolinyl)phenyl)-6-methoxy-, (alphaS)-, M 3814, M-3814, M3814, MSC 2490484A, MSC-2490484A, MSC2490484A, Nedisertib
National Cancer Institute (NCI)
Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Undifferentiated Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Carcinosarcoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Ovarian Mucinous Adenocarcinoma, Recurrent Ovarian Transitional Cell Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma
06/25
06/25
NCT05985681: Testing RG1-VLP Vaccine to Prevent HPV-related Cancers

Not yet recruiting
1
33
Europe, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, HPV16 RG1 VLP Vaccine, 16L1-16L2aa17-36-based Vaccine, HPV16 RG1-VLP, HPV16-RG1VLPs, RG1-VLP Vaccine, RG1-VLPs, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine, Gardasil 9, Nonavalent HPV VLP Vaccine, Recombinant HPV Nonavalent Vaccine, Recombinant Human Papillomavirus 9-valent Vaccine, Saline, ISOTONIC SODIUM CHLORIDE SOLUTION, Normal Saline, Sodium Chloride 0.9%
National Cancer Institute (NCI)
Human Papillomavirus-Related Carcinoma
06/26
06/27
SOROCk, NCT04251052: A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Recruiting
N/A
2262
Canada, US, RoW
Bilateral Salpingectomy, Bilateral Salpingectomy with Oophorectomy, bilateral salpingo-oophorectomy, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Transvaginal Ultrasound, transvaginal sonography, TVS, TVU, Ultrasound Imaging, 2-Dimensional Grayscale Ultrasound Imaging, 2-Dimensional Ultrasound Imaging, 2D-US, Ultrasonography, Ultrasound, Ultrasound Test, Ultrasound, Medical, US
NRG Oncology, National Cancer Institute (NCI)
Ovarian Carcinoma
06/36
06/37
Hernando, Diego
NCT06675357: Using FAPI PET/MRI to Evaluate Prostate Cancer

Recruiting
2
30
US
FAPI, Positron Emission Tomography (PET), Magnetic Resonance Imaging
University of Wisconsin, Madison
Prostate Cancer Metastatic Disease, Prostate Cancers
10/26
10/26
NCT04631718: MRI QSM Imaging for Iron Overload

Completed
N/A
63
US
Magnetic Resonance Imaging (MRI)-based Quantitative Susceptibility Mapping (QSM)
University of Wisconsin, Madison, Stanford University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hemochromatosis, Iron Overload
04/24
04/24
NCT06354491: An Imaging-based Quantitative Biomarker Assay for NAFLD in Children

Recruiting
N/A
24
US
Magnetic Resonance Imaging (MRI), Ultrasound (US)
University of Wisconsin, Madison
NAFLD, NASH
04/26
04/27
NCT05261633: Diffusion MRI of the Abdomen

Recruiting
N/A
80
US
Diffusion Weighted Magnetic Resonance Imaging, DW-MRI
University of Wisconsin, Madison, National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Abdominal Imaging
09/25
09/25
Westergaard, Ryan
NCT04268173: Community-Based, Client-Centered Prevention Homes to Address the Rural Opioid Epidemic- Aim 3

Completed
N/A
343
US
Community-Based, Client-Centered Prevention Home, Prevention Navigation
University of Wisconsin, Madison, Tulane University, National Institute on Drug Abuse (NIDA)
Drug Use Disorders, Hepatitis C, Harm Reduction, Opioid-use Disorder
07/23
07/23
CJC-TraC, NCT05376371: Criminal Justice Coordinated Transitional Care

Active, not recruiting
N/A
219
US
CJC-TraC
University of Wisconsin, Madison, National Institute on Drug Abuse (NIDA)
HIV, Hepatitis C, Substance Use Disorders
02/25
09/25
NCT06109571: Clinic-level Implementation of mHealth to Improve HIV Viral Suppression for Patients With Substance Use Disorders

Enrolling by invitation
N/A
806
US
Connections App
University of Wisconsin, Madison, National Institute on Drug Abuse (NIDA)
HIV Infections, Substance Use Disorders
03/27
03/27
Sadowski, Elizabeth
NCI-2018-00466, NCT03302156: PSMA PET and MRI in Gynecological Cancers

Terminated
2
15
US
PSMA-based 18F-DCFPyL PET tracer, PSMA
University of Wisconsin, Madison
Gynecologic Cancer
01/20
01/20
Fowler, Amy M
NCI-2018-02281, NCT03703492: Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS

Completed
2
13
US
(18F)FES, 11.2 16α-[18F]-fluoro-17β-estradiol, FES, Gadobenate dimeglumine, MultiHance
University of Wisconsin, Madison, National Cancer Institute (NCI), National Center for Advancing Translational Sciences (NCATS)
Breast Cancer, Ductal Carcinoma in Situ - Category
01/24
01/24
NCT03212170: FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer

Active, not recruiting
2
20
US
[18F]Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging, FFNP
University of Wisconsin, Madison, National Center for Advancing Translational Sciences (NCATS)
Invasive Breast Cancer
11/24
12/25
DIRECT, NCT05710328: Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The Trial

Recruiting
2
235
US
Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Surgical Procedure, Operation, Surgery, Surgery Type, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery
ECOG-ACRIN Cancer Research Group
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma
05/27
12/29
NCT06086704: Study of 18F-FFNP Breast PET/MRI

Recruiting
2
53
US
18F-fluorofuranylnorprogesterone, FFNP, Positron Emissions Tomography / Magnetic Resonance Imaging, PET/MRI, Anastrozole, Blood Sampling, FDA-approved gadolinium-based intravenous contrast agent, gadopiclenol, gadobenate dimuglumine
University of Wisconsin, Madison, National Cancer Institute (NCI)
Breast Cancer
01/27
01/30
NCT04316117: Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study

Active, not recruiting
2
138
Europe, US
Computed Tomography, CAT, CAT scan, computerized axial tomography, Computerized Tomography, CT, CT scan, tomography, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, positron emission tomography scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
08/27
08/27
NCT03393741: Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy

Terminated
N/A
5
US
Taxane, paclitaxel, nab-paclitaxel, docetaxel, Vinorelbine, vinca alkaloid, Ixabepilone, epothilone, Eribulin, halichondrins, Chemotherapy
University of Wisconsin, Madison, National Cancer Institute (NCI)
Breast Cancer, Breast Neoplasms
02/24
02/24
NCT00904241: Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Recruiting
N/A
10000
Europe, Canada, US, RoW
Cytology Specimen Collection Procedure, Cytologic Sampling, Laboratory Biomarker Analysis
Children's Oncology Group, National Cancer Institute (NCI)
Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
01/00
 
NCT00736749: Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Recruiting
N/A
5000
US
Assessment of Therapy Complications, Questionnaire Administration
Children's Oncology Group, National Cancer Institute (NCI)
Hematopoietic Cell Transplantation Recipient, Leukemia, Solid Tumor
01/00
 
Huckfeldt, Rachel M
NCT04671433 / 2020-002873-88: Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Completed
3
97
Europe, Canada, US, RoW
Genetic: AAV5-hRKp.RPGR, botaretigene sparoparvovec
Janssen Research & Development, LLC, Janssen Research & Development, LLC
X-Linked Retinitis Pigmentosa
09/24
09/24
NAC Attack, NCT05537220: Oral N-acetylcysteine for Retinitis Pigmentosa

Recruiting
3
438
Europe, Canada, US, RoW
N-acetylcysteine, Placebo
Johns Hopkins University, National Eye Institute (NEI), Duke University, Emory University, Massachusetts Eye and Ear Infirmary, Mayo Clinic, Medical College of Wisconsin, Retina Foundation of the Southwest, Stanford University, University of California, Davis, University of Florida, University of Iowa, University of Miami, University of Michigan, University of Minnesota, University of Oklahoma, University of Southern California, University of Utah, University of Washington, University of Wisconsin, Madison, Vanderbilt University, Vitreo Retinal Associates, PA, University of Houston, Medical University of Graz, McGill University, Universität Tübingen, Centro Medico ABC, Radboud University Medical Center, University of Amsterdam, University Hospital, Basel, Switzerland, University College London Hospitals, Northwestern University, University of Pennsylvania
Retinitis Pigmentosa
12/28
12/28
MGT-RPGR-022, NCT04794101 / 2020-002255-37: Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Active, not recruiting
3
97
Europe, Canada, US, RoW
Genetic: AAV5-hRKp.RPGR Intermediate Dose, botaretigene sparoparvovec, Genetic: AAV5-hRKp.RPGR Low Dose
Janssen Research & Development, LLC, Janssen Research & Development, LLC
X-Linked Retinitis Pigmentosa
09/29
12/29
NCT04312672 / 2018-000425-31: Long-term Follow-up Gene Therapy Study for RPGR- XLRP

Active, not recruiting
1/2
42
Europe, US
AAV5-hRKp.RPGR
Janssen Research & Development, LLC, MeiraGTx UK II Ltd, Janssen Research & Development, LLC
X-Linked Retinitis Pigmentosa
11/26
11/26
POLARIS, NCT06435000: An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

Recruiting
N/A
75
Europe, US
Splice Bio
Stargardt, Stargardt's Disease, Stargardt Disease, STGD1
12/26
02/27
Uni-Rare, NCT05589714: Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants

Recruiting
N/A
1500
Europe, Canada, US, RoW
Jaeb Center for Health Research, Foundation Fighting Blindness
Inherited Retinal Degeneration, Retinitis Pigmentosa
12/28
12/28
GYROS, NCT05312736: Gyrate Atrophy Ocular and Systemic Study

Recruiting
N/A
45
Europe, Canada, US, RoW
Jaeb Center for Health Research, Conquering Gyrate Atrophy Foundation, Foundation Fighting Blindness
Gyrate Atrophy, Gyrata of Choroid and Retina; Atrophy, Ornithine-δ-aminotransferase, OAT, Chorioretinal Degeneration
12/28
06/29
Schrage, William G
NCT06253702: Brain Blood Flow Responses to Stress: Sex Differences

Recruiting
4
26
US
Indomethacin, Indo, Placebo, Orilissa, Testosterone gel, Anastrozole, Estradiol
University of Wisconsin, Madison, National Heart, Lung, and Blood Institute (NHLBI)
Cerebrovascular Disorders
03/25
05/26
Gas Challenge, NCT04265053: Human Cerebral Blood Flow Regulation

Recruiting
1
111
US
Indomethacin 25 MG/50 MG, Placebo - Lactose, Ganirelix Acetate, Testosterone Transdermal Product, Estradiol Topical, Antacid
University of Wisconsin, Madison, National Heart, Lung, and Blood Institute (NHLBI)
Cerebral Arterial Diseases
03/25
05/26
NCT04154865: Exercise in Adolescents With Insulin Resistance

Terminated
N/A
15
US
Hypercapnia, CO2, Transcranial Doppler, TCD, Cycle ergometer, Stationary bike, Cognitive Tests
University of Wisconsin, Madison
Insulin Resistance
11/21
11/21
NCT05958303: HYPEROXIA Responses and ROS

Recruiting
N/A
30
US
Antioxidant Cocktail, AOC, Placebo
University of Wisconsin, Madison, National Heart, Lung, and Blood Institute (NHLBI)
Cerebrovascular Disorders
08/25
08/26
Samsonov, Alexey
NCT04415372: Macromolecular Imaging of White and Gray Matter Pathology in Multiple Sclerosis

Enrolling by invitation
N/A
75
US
MRI, Functional MRI, Neuropsychological Testing
University of Wisconsin, Madison, National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Multiple Sclerosis, MS
04/25
04/27
Adamczyk, Peter R
NCT04275973: Evaluating Mobility Interventions in the Real World

Completed
N/A
29
US
Lower limb prostheses, Orthoses for Drop-foot, Footwear
University of Wisconsin, Madison, United States Department of Defense
Lower Limb Amputation, Drop Foot
08/24
08/24
Strigel, Roberta
NCT03212170: FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer

Active, not recruiting
2
20
US
[18F]Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging, FFNP
University of Wisconsin, Madison, National Center for Advancing Translational Sciences (NCATS)
Invasive Breast Cancer
11/24
12/25
NCT06086704: Study of 18F-FFNP Breast PET/MRI

Recruiting
2
53
US
18F-fluorofuranylnorprogesterone, FFNP, Positron Emissions Tomography / Magnetic Resonance Imaging, PET/MRI, Anastrozole, Blood Sampling, FDA-approved gadolinium-based intravenous contrast agent, gadopiclenol, gadobenate dimuglumine
University of Wisconsin, Madison, National Cancer Institute (NCI)
Breast Cancer
01/27
01/30
Mahajan, Aparna
NCT03212170: FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer

Active, not recruiting
2
20
US
[18F]Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging, FFNP
University of Wisconsin, Madison, National Center for Advancing Translational Sciences (NCATS)
Invasive Breast Cancer
11/24
12/25
NCT06086704: Study of 18F-FFNP Breast PET/MRI

Recruiting
2
53
US
18F-fluorofuranylnorprogesterone, FFNP, Positron Emissions Tomography / Magnetic Resonance Imaging, PET/MRI, Anastrozole, Blood Sampling, FDA-approved gadolinium-based intravenous contrast agent, gadopiclenol, gadobenate dimuglumine
University of Wisconsin, Madison, National Cancer Institute (NCI)
Breast Cancer
01/27
01/30
Aagaard-Kienitz, Beverly
NCT05536895: C-arm Cone Beam CTP Guided Cerebrovascular Interventions

Not yet recruiting
N/A
90
US
C-Arm Cone Beam Computed Tomography, C-ARM CBCT, Multi-detector Computed Tomography, MD-CT
University of Wisconsin, Madison, National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Acute Ischemic Stroke
03/26
03/26
Chen, Guang-Hong
NCT05536895: C-arm Cone Beam CTP Guided Cerebrovascular Interventions

Not yet recruiting
N/A
90
US
C-Arm Cone Beam Computed Tomography, C-ARM CBCT, Multi-detector Computed Tomography, MD-CT
University of Wisconsin, Madison, National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Acute Ischemic Stroke
03/26
03/26
Connect, Cancer
NCT03096418: Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response

Recruiting
4
50
US
Paclitaxel, Taxol
University of Wisconsin, Madison, National Cancer Institute (NCI)
Breast Neoplasm Female
06/26
06/26
ROCKnrol-1, NCT06143891: A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.

Recruiting
3
260
Europe, Canada, US, RoW
Belumosudil, SAR445761/ KD025, REZUROCK, Placebo, Prednisone, Prednisolone
Sanofi
Chronic Graft Versus Host Disease
09/28
09/28
NCI-2018-00466, NCT03302156: PSMA PET and MRI in Gynecological Cancers

Terminated
2
15
US
PSMA-based 18F-DCFPyL PET tracer, PSMA
University of Wisconsin, Madison
Gynecologic Cancer
01/20
01/20
SMILE, NCT04738292: Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The Study)

Terminated
2
11
US
Onapristone, Fulvestrant, Fulvestrant Injection
University of Wisconsin, Madison, Context Therapeutics Inc.
ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Cancer
04/23
05/23
NCT03311126: Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma

Terminated
2
21
US
Bendamustine, Obinutuzumab, GA101, RO5072759
University of Wisconsin, Madison, Genentech, Inc.
Mantle Cell Lymphoma, Non-hodgkin Lymphoma, Non Hodgkin Lymphoma
07/23
07/23
SGNTUC-019, NCT04579380 / 2020-004873-29: Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Active, not recruiting
2
217
Europe, Japan, US, RoW
tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab, Herceptin, fulvestrant, Faslodex
Seagen Inc., Seagen, Inc.
Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
11/23
05/25
NCI-2018-02551, NCT03725761: Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy

Active, not recruiting
2
31
US
Sacituzumab Govitecan, IMMU-132
University of Wisconsin, Madison, National Cancer Institute (NCI), Gilead Sciences
Prostate Cancer
04/24
04/25
KEYNOTE-C86, NCT04993677 / 2021-002037-42: A Study of SEA-CD40 Given With Other Drugs in Cancers

Active, not recruiting
2
77
Europe, Canada, US
SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed, Alimta, carboplatin, Paraplatin
Seagen Inc., Merck Sharp & Dohme LLC
Melanoma, Carcinoma, Non-Small- Cell Lung
01/24
10/25
IGNYTE, NCT03767348 / 2016-004548-12: Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

Hourglass Jan 2024 - Mar 2024 : Data from IGNYTE trial in combination with Opdivo for 2L melanoma
Checkmark From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020
Nov 2020 - Nov 2020: From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020
Checkmark Initial data from P1 portion of trial in combination with RP1 at SITC 2019
Nov 2019 - Nov 2019: Initial data from P1 portion of trial in combination with RP1 at SITC 2019
Recruiting
2
340
Europe, US
RP1, nivolumab, Opdivo
Replimune Inc., Bristol-Myers Squibb
Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC
12/25
12/28
NCT03943901: Split-Dose R-CHOP for Older Adults With DLBCL

Active, not recruiting
2
26
US
Rituximab, Rituxan, Cyclophosphamide, Cytoxan, Doxorubicin, Adriamycin, Vincristine, Prednisone, Pegfilgrastim, filgrastim
University of Wisconsin, Madison, Medical College of Wisconsin
Diffuse Large B Cell Lymphoma, DLBCL, Cancer
02/25
02/27
BTCRC LUN20-462, NCT04919382: Temozolomide and Atezolizumab as Second or Third Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

Recruiting
2
56
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZ
Dwight Owen, Genentech, Inc.
Extensive Stage Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
12/25
12/26
DisTinGuish, NCT04363801: A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

Hourglass Oct 2023 - Mar 2024 : Q4'23/Q1'24 - Initial ORR data from DisTinGuish trial for 2L gastric cancer
Oct 2023 - Dec 2023: Initial data from part C of DisTinGuish trial in combination with tislelizumab for 1L gastric cancer
Checkmark Updated data from part B of DisTinGuish trial in combination with tislelizumab for 2L gastric cancer
Nov 2022 - Nov 2022: Updated data from part B of DisTinGuish trial in combination with tislelizumab for 2L gastric cancer
Checkmark ORR, PFS and OS data from DisTinGuish trial in combination with tislelizumab for gastroesophageal junction cancer or gastric cancer
More
Active, not recruiting
2
232
Europe, US, RoW
DKN-01 300mg, DKN-01 600mg, DKN-01 400mg, Tislelizumab 200mg, Tislelizumab 400mg, Oxaliplatin, Capecitabine 1000mg/ m2 BID, Xeloda, Leucovorin Calcium, Folinic acid, Fluorouracil
Leap Therapeutics, Inc., BeiGene
Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer
06/25
12/25
NCT04587128: Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC

Recruiting
2
71
US
Panitumumab, Cetuximab, Irinotecan, FOLFIRI Protocol, Bevacizumab
University of Wisconsin, Madison, Doris Duke Charitable Foundation
Metastatic Colorectal Cancer
10/25
10/25
NCT05846646: Study of PULSAR-ICI +/- IMSA101 in Patients with Oligometastatic NSCLC and RCC

Terminated
2
6
US
IMSA101, Immune checkpoint inhibitor, pembrolizumab, nivolumab, PULSAR
ImmuneSensor Therapeutics Inc.
Oligometastatic Disease
09/24
09/24
NCT05846659: Study of PULSAR-ICI +/- IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies

Terminated
2
16
US
IMSA101, Immune checkpoint inhibitor, pembrolizumab, nivolumab, PULSAR
ImmuneSensor Therapeutics Inc.
Oligoprogressive
11/24
11/24
NCT01743950: A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab

Terminated
2
49
US
Bevacizumab, PRDR, re-irradiation
University of Wisconsin, Madison, Genentech, Inc., National Cancer Institute (NCI)
Glioma
12/24
12/24
NCI-2019-07966, NCT04150640: Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma

Recruiting
2
52
US
Nal-IRI, liposomal irinotecan, Oxaliplatin, 5-FU, Fluorouracil, Trastuzumab, Pembrolizumab, Nivolumab
University of Wisconsin, Madison, Ipsen
Esophageal Adenocarcinoma, Gastric Adenocarcinoma
12/25
12/26
NCT05988918: Multicenter Trial of ESK981 in Patients With Select Solid Tumors

Recruiting
2
66
US
ESK981, CEP-11981
University of Michigan Rogel Cancer Center
Pancreatic Adenocarcinoma, Adenosquamous Carcinoma, Pancreatic Neuroendocrine Tumor, Pancreatic Neuroendocrine Carcinoma, Gastrointestinal Neuroendocrine Tumor, Gastrointestinal Neuroendocrine Carcinoma, Neuroendocrine Prostate Carcinoma
04/27
04/29
NCT05109494: Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas

Recruiting
2
30
US
Conventional Fractionated, Hypofractionated
University of Wisconsin, Madison
Soft Tissue Sarcoma
11/26
11/26
MAPBI, NCT03936478: Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer

Recruiting
2
30
US
MRIdian Radiation Treatment Unit
University of Wisconsin, Madison
Breast Cancer, DCIS, LCIS
01/27
01/31
 

Download Options